EXOZYMES INC. Revenue
EXOZYMES INC. (EXOZ) reported Revenue of $70.07 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-03-31
- EXOZYMES INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-12-31 was -$700.00.
- EXOZYMES INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $70.07K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|
| 2023-12-31 | -$700.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $70.07K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $70.77K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |